These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36443902)

  • 21. The 21st Annual Prostate Cancer Foundation Scientific Retreat report.
    Miyahira AK; Simons JW; Soule HR
    Prostate; 2015 Aug; 75(11):1119-28. PubMed ID: 25893521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 29th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Miyahira AK; Soule HR
    Prostate; 2024 Feb; 84(2):113-130. PubMed ID: 37915138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
    Miyahira AK; Pienta KJ; Morris MJ; Bander NH; Baum RP; Fendler WP; Goeckeler W; Gorin MA; Hennekes H; Pomper MG; Sartor O; Tagawa ST; Williams S; Soule HR
    Prostate; 2018 Aug; 78(11):775-789. PubMed ID: 29717499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data-driven translational prostate cancer research: from biomarker discovery to clinical decision.
    Lin Y; Zhao X; Miao Z; Ling Z; Wei X; Pu J; Hou J; Shen B
    J Transl Med; 2020 Mar; 18(1):119. PubMed ID: 32143723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer.
    Naitoh J; Witte O; Belldegrun A
    Cancer Res; 1998 Jul; 58(13):2895-900. PubMed ID: 9661908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proceedings of the 3rd International Conference for Cancer Metabolism and Therapy, October 12-14, 2018, Shanghai, China.
    Xiao GG; Zhang Z; Lu B; Wang H; Fan TW; Boros LG; Gao P; Pan Y; Go VLW
    Pancreas; 2020 Feb; 49(2):149-157. PubMed ID: 32049950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
    Bou-Dargham MJ; Sha L; Sang QA; Zhang J
    BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 20th Annual Prostate Cancer Foundation Scientific Retreat report.
    Miyahira AK; Simons JW; Soule HR
    Prostate; 2014 Jun; 74(8):811-9. PubMed ID: 24719035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions.
    Pantuck AJ; Zisman A; Belldegrun AS
    World J Urol; 2000 Apr; 18(2):143-7. PubMed ID: 10854150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Commentary on: "Satisfaction with information used to choose prostate cancer treatment." Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.: J Urol 2014;191(5):1265-71. doi:10.1016/j.juro.2013.12.008. [Epub 2013 Dec 12].
    Brent H
    Urol Oncol; 2016 May; 34(5):247-8. PubMed ID: 25990613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New horizons in bladder cancer research.
    Boormans JL; Zwarthoff EC; Black PC; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Williams SB; Schmitz-Dräger BJ
    Urol Oncol; 2020 Dec; 38(12):867-885. PubMed ID: 30852032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?
    Isaacs JT
    Am J Clin Exp Urol; 2018; 6(2):55-61. PubMed ID: 29666833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA.
    Marquardt J; Begent RH; Chester K; Huston JS; Bradbury A; Scott JK; Thorpe PE; Veldman T; Reichert JM; Weiner LM
    MAbs; 2012; 4(6):648-52. PubMed ID: 23007482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging Biomarker-Guided Therapies in Prostate Cancer.
    Deluce JE; Cardenas L; Lalani AK; Maleki Vareki S; Fernandes R
    Curr Oncol; 2022 Jul; 29(7):5054-5076. PubMed ID: 35877260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.
    Crawford ED; Bryce AH; Hussain MH; Agarwal N; Beltran H; Cooperberg MR; Petrylak DP; Shore N; Spratt DE; Tagawa ST; Antonarakis ES; Aparicio AM; Armstrong AJ; Boike TP; Calais J; Carducci MA; Chapin BF; Cookson MS; Davis JW; Dorff T; Eggener SE; Feng FY; Gleave M; Higano C; Iagaru A; Morgans AK; Morris M; Murray KS; Poage W; Rettig MB; Sartor O; Scher HI; Sieber P; Small E; Srinivas S; Yu EY; Zhang T; Koo PJ
    JU Open Plus; 2024 Apr; 2(4):. PubMed ID: 38774466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.
    Alarcón-Zendejas AP; Scavuzzo A; Jiménez-Ríos MA; Álvarez-Gómez RM; Montiel-Manríquez R; Castro-Hernández C; Jiménez-Dávila MA; Pérez-Montiel D; González-Barrios R; Jiménez-Trejo F; Arriaga-Canon C; Herrera LA
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):431-443. PubMed ID: 35422101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. American Society of Clinical Oncology--34th Annual Meeting. Treatments for prostate cancer and new molecular targets. 16-19 May 1998, Los Angeles, California, USA.
    McKinnon C
    IDrugs; 1998 Jun; 1(2):163-7. PubMed ID: 18465522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
    Lu C; Brown LC; Antonarakis ES; Armstrong AJ; Luo J
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):381-397. PubMed ID: 32139878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarker-driven immunotherapy for precision medicine in prostate cancer.
    Ottini A; Sepe P; Beninato T; Claps M; Guadalupi V; Verzoni E; Giannatempo P; Baciarello G; de Braud F; Procopio G
    Per Med; 2022 Jan; 19(1):51-66. PubMed ID: 34873959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.